Compare ImmunityBio Inc. Common Stock (IBRX) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Marsh & McLennan Companies, Inc. — how do they compare? ImmunityBio Inc. Common Stock trades at $10 (market cap $10.51B), while Marsh & McLennan Companies, Inc. trades at $176.51 (market cap $84.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 8× ImmunityBio Inc. Common Stock's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| IBRX | MRSH | |
|---|---|---|
Market Cap | $10.51B | $84.31B |
Volume | 10,445,785 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $11.55 | $207.02 |
52-Week Low | $1.98 | $157.32 |
Typical Hold Time | 0 Days | 109 Days |
Enterprise Value | $10.97B | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Marsh (MRSH) trades at $173.66, up 1.11% today, with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with consistent revenue growth from $20.7B in 2022 to $27.0B in 2025, and net income reaching $4.16B. Recent acquisition of Accel Holdings (October 2026) enhances its insurance advisory footprint. Valuation metrics include a P/E of 21.2 and ROE of 25.72%, indicating efficient capital use. Cash flow remains positive with $486M net inflow in 2025.
Outlook is cautiously optimistic with a consensus price target of $202.71 (17% upside), though 65% of analysts rate Hold. Risks include rising debt-to-asset ratio (35.43% in 2024) and potential margin pressure as net income margin dips to 14.24% in 2026. The stock's proximity to resistance at $174 requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
